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Summary 
To investigate the development of HLA-DR-associated autoimmune  diseases,  we generated 
transgenic (Tg) mice with HLA-DRA-IEcx and HLA-DRBI*0401-IE[3 chimeric genes.  The 
transgene-encoded proteins consisted of antigen-binding domains from HLA-DRA and HLA- 
DRBI*0401 molecules and the remaining domains from the IEd-ot and IEd-[3 chains. The chi- 
meric molecules showed the same antigen-binding specificity as HLA-DRBI*0401 molecules, 
and were functional in presenting antigens to T  cells. The Tg mice were backcrossed to MHC 
class II-deficient (IAl3-,IEoe-) mice to eliminate any effect of endogenous MHC class II genes 
on the development of autoimmune diseases. As expected, IA~x[3 or IEot[3 molecules were not 
expressed in Tg mice. Moreover, cell-surface expression of endogenous IE[3 associated with 
HLA-DRA-IEci was not detectable in several Tg mouse lines by flow cytometric analysis. The 
HLA-DRA-IEo~/HLA-DRBI*0401-IE[3 molecules rescued the development ofCD4  + T  cells 
in MHC class II-deficient mice, but T  cells expressing VI35, V1311, and VI312 were specifically 
deleted. 
Tg mice were immunized with peptides, myelin basic  protein (MBP)  87-106 and proteo- 
lipid protein (PLP)  175-192,  that are considered to be immunodominant  epitopes in HLA- 
DR4 individuals. PLP175-192 provoked a strong proliferative response of lymph node T  cells 
from Tg mice, and caused inflammatory lesions in white matter of the CNS and symptoms of 
experimental allergic encephalomyelitis (EAE). Immunization with MBP87-106 elicited a very 
weak proliferative T  cell response and caused mild EAE. Non-Tg mice immunized with either 
PLP175-192 or MBP87-106 did not develop EAE. These results  demonstrated that a human 
MHC class II binding site alone can confer susceptibility to an experimentally induced murine 
autoimmune disease. 
S 
ince  HLA-DR4 allele is  associated with  the  develop- 
ment  of autoimmune  diseases  such  as  rheumatoid ar- 
thritis  (RA) 1  and  multiple  sclerosis  (MS),  HLA-DR4/ 
human  CD4  Tg mice  and  HLA-DR.4-IE  Tg mice  have 
been generated to investigate these diseases. These Tg mice 
are functional in activation of HLA-DR4-restricted T  cells 
(1, 2). However, since the Tg mice express both HLA-DR 
and  endogenous  mouse  MHC  class  II  molecules,  both 
1Abbreviations used in this paper: EAE, experimental  allergic encephalomy- 
elitis; HA, Flu virus hemagglutinin; MBP, myelin  basic protein; MMTV, 
mouse mammary tumor virus; MS, multiple sclerosis; PLP, proteolipid 
protein; RA, rheumatoid  arthritis; Tg, transgenic. 
HLA-DR- and mouse MHC class II-restricted T  cells are 
activated in response to antigens. Thus, the effect of HLA- 
DR on immune response and susceptibility to autoimmune 
disease  is  difficult to  separate  from that  of the  wild-type 
murine MHC class II molecules. In the present study, we 
produced HLA-DRA-IEcx/HLA-DRBI*0401-IE[3 Tg mice, 
and backcrossed them to MHC  class II-deficient mice to 
eliminate any effect of endogenous MHC class II proteins. 
P~ecendy, the same strategy has been applied to HLA-DQ8 
Tg mice (3). 
MBP and PLP are putative autoantigens involved in the 
pathogenesis of MS and can induce EAE in mice and rats 
(4-6). Disease in these animal models can also be induced 
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syngeneic recipients (7). In humans, MBP- or PLP-reactive 
HLA-DR-restricted T  cells have  been  isolated from both 
MS patients and healthy controls (8-13). MBP-specific T  cells 
in  MS  patients  were  activated while  those  from  controls 
were in a resting state (13). Activated MBP- and PLP-reac- 
tive T  cells might therefore be i/avolved in the pathogenesis 
of MS. We show here that immunization of HLA-DRA- 
IEc~/HLA-DRBI*0401-IE[3  Tg  mice  with  PLP175-192 
or MBP87-106  peptides induces the development of EAE. 
Materials  and Methods 
Gene  Constructs of HLA-DRA-IE~ol  and  HLA-DRBI*O401- 
IEar  The DNA carrying exon 2 of HLA-DRA was amplified 
from pPR541  cosmid DNA  (14) with  primers,  5'  ACAGAA- 
GGTGTCAGGTAGACTTGAAA3' and 5' GAGCACAGTTAC- 
CTCTGGAGGTAC3'  by  polymerase  chain  reaction  (PCR) 
using Pfu  DNA polymerase. The  amplicon carrying the  HLA- 
DRA  exon  2  was  treated with T4  DNA polymerase and sub- 
cloned into the Sinai site of pBluescript vector (Stratagene, San 
Diego, CA). An 8-kb BglI fragment of IEda gene derived from 
no. 32.1  IEdoI cosmid DNA (15) was also treated with T4 DNA 
polymerase and subcloned into the Smal site of pBluescript vec- 
tor. The IEdct genomic DNA, from which exon 2 was removed 
by BstEII and BgllI digestion, was treated with Klenow Fragment 
ofDNA polymerase I. This DNA was then ligated to the 1.5-kb 
DNA  fragment carrying HLA-DRA exon  2  that  was  digested 
from  pBluescript  vector  with  EcoRV  and  Bspl06  and  then 
treated with Klenow Fragment ofDNA polymerase I. 
A 7-kb EcoRI/KpnI DNA fragment carrying IEa[~ exon 1 was 
ligated to  a  10-kb  EcoRI/KpnI  DNA  fragment  carrying IEal3 
exon 3-6  (16).  The ligated DNA was subcloned into the KpnI 
site ofpBluescript vector. The DNA fragment containing Exon 2 
of HLA-DRBI*0401  was  amplified  from  genomic  DNA  of 
Priess cells by PCR using Taq polymerase and primers, 5' TGA- 
AAGCGGTGCGTGCTGTTTAA3' and 5' CCCCATACATTT- 
CCCTTCCTTG3'.  It was then subcloned into a pCRII vector 
(Invitrogen, San Diego,  CA).  The  0.85-kb  EcoRI  DNA  frag- 
ment  carrying exon  2  of HLA-DRBI*0401  was  ligated to  the 
EcoRI site of the IEdl3 genomic DNA which lacks exon 2. 
Transgenic Mice.  The  gene  constructs  were  removed  from 
plasmid by digestion with Not I and Bspl06 for HLA-DRA-IEder 
and KpnI for HLA-DRBI*0401-IE[3. They were coinjected into 
C57BL/6  fertilized eggs.  Tg  mice  were  backcrossed  to  C2D 
(IA[3-,IEet-) mice on the C57BL/6 genetic background. Tg foun- 
ders were first identified by PCR with 5' GGGAAGCAGGGG- 
GACTATGAC3' and  5'  TTAGGGCAATGACTTCGTAGG3' 
primers for HLA-DRA-IEot and 5'  TGAAAGCGGTGCGTG- 
CTGTTTAA3'  and  5'  CACCCGCTCCGTCCCGTTGAA3' 
primers for HLA-DPd31*0401-IE~, and were then confirmed by 
southern blot analysis using probes derived from exon 2 of HLA- 
DRA and HLA-DRBI*0401  genes and by staining of peripheral 
blood  cells  using  anti-HLA-DR  mAb,  L243.  C57BL/6  mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME), 
and  C2D  mice  were  purchased  from  GenPharm  International 
(Mountain View, CA). 
Flow Cytometry Analysis.  Spleen cells or thymocytes (5 X  1(15) 
were suspended in 100  p~l of RPMI medium containing 2% FCS 
and 0.1%  sodium azide and incubated on ice in the presence of 
mAb for 30 rain. The cells were washed twice with PBS contain- 
ing 0.1% sodium azide and 0.1%  BSA, and then once with PBS 
containing  0.1%  sodium  azide.  The  cells were  analyzed  on  a 
FACSort  |  using LYSIS II software. The  following mAbs were 
used in the experiments: Anti-HLA-DR mAb, L243;  anti-B220 
mAb,  RA3-6B2;  anti-CD11[3  mAb,  M1/70;  anti-IEI3  mAb, 
17.3.3; anti-IA  b mAb, AF6-120.1; anti-mouse CD4 mAb, RM4-5; 
anti-mouse CD8  mAb,  53-6.7;  anti-V[3  Abs (VI32, B20.6;  V133, 
KJ25; V[34, KJ4; VI35, MR9-4; V136, RR4-7; V[37, TR310; VI38, 
MR5-2;  VI39, MR10-2;  V1310, B21.5; V[311,  RR3-15;  VI312, 
MR11-1; VIB13, MR12-3; VI314, 14-2; VI317, KJ-23). The anti- 
HLA-DR mAb was purchased from Becton Dickinson (San Jose, 
CA), and all other mAbs were purchased from PharMingen (San 
Diego, CA). 
T Cell Proliferation Assay.  Mice were primed in the base of the 
tail with 50-200  Ixg of peptide in Complete Freund's Adjuvant 
(CFA). 9  d  later, inguinal and paraortic lymph node cells were 
isolated and assayed for T  cell proliferation using 4  ￿  105 cells/ 
well. The cells were cultured with an antigen for 63 h in RPMI 
medium containing 10% FCS, 50  u/ml penicillin/streptomycin, 
2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential 
amino acids,  and 0.25  txg/ml fungizone. The  cells were pulsed 
with 2 I.~Ci[methyl-3H]thymidine for 6-9 h, then harvested and 
counted in a scintillation counter. 
Peptide Binding Assay.  Peptides were prepared using solid phase 
synthesis procedures as described (17).  Their sequences  are de- 
scribed in Table 1.  MHC  class II molecules were purified from 
Table 1.  Antigen Binding Specificity to DRBI*O4OI-IE 
Peptides  Sequence 
50% Inhibitory Concentration (IC50, }aM) 
DRBI*0401  DRBI*0401-IE 
m 1-7  YRAMATL 
S6-m1-7  YRAMASL 
A6-m1-7  YRAMAAL 
R6-ml-7  YRAMARL 
HA307-319  PKYVKQNTLKLAT 
HA-R6  PKYVKQNRLKLAT 
MBP87-106  WHFFKNIVTPRTPPPSQGK 
PLP175-192  YIYFNTWTTCQSIAFPSK 
0.120  0.130 
0.043  0.053 
0.410  0.530 
> 10  3.300 
0.245  0.220 
>10  >1(1 
0,158  0.153 
0.187  0.169 
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M12.C3  cells (18) transfected  with  HLA-DRA-IEci and HLA- 
DRBI*0401-IE]3 genes. Transfection was carried out with 10 ixg 
of NotI-digested Neor-HLA-DR.A-IEot and 20  Ixg of KpnI- 
digested HLA-DRBI*0401-1E]3 under 960 mFD and 0.25 kV by a 
Bio-R.ad Gene Pulser  TM. The binding peptides  used in the study 
were radioiodinated using IODO-BEADS (Pierce, Rockford, IL) 
and the labeled  peptide was separated  from free 125I by a Seppak 
C-18 column. The binding reactions  were performed in 96-well 
Optiplates  (Packard  Instrument,  Downers  Grove,  IL),  which 
were blocked with  1 p,g/ml BSA in PBS.  The affinity-purified 
MHC class II molecules  (0.1-1  I.Lg), 75 nM 12SI-radiolabeled pep- 
tide, and various concentrations  of  competitor peptides were mixed 
in binding buffer (50 mM PBS, pH 7.5, 1% NP-40, 6 mM N-eth- 
ylmaleimide,  1 mM PMSF, 1.6 mM EDTA and a cocktail of  pro- 
tease  inhibitors;  aprotinin  (100  U/M),  leupeptin  (10  p.g/ml), 
pepstatin  A  (10  I~g/ml).  After an  18-24-h incubation at  room 
temperature,  10  txl  of anti-HLA-DR mAb  (LB3.1)-conjugated 
SPA beads (Amersham Corp., Arlington Heights, tL) were added 
at a dilution of 1:7. After a 1-2-h incubation at room tempera- 
ture,  with gentle shaking,  the plates were heat sealed and peptide 
binding was  quantitated  in  a  Packard  Top  Count  Scintillation 
counter. 
EAE Induction.  EAE was induced by subcutaneous injection 
of 400 btg of peptides  emulsified  in CFA containing 250 txg of 
H37R.a Mycobacterium tuberculosis. 7 d later, mice were boosted by 
a second subcutaneous injection of the same amount of antigens 
used in the primary immunization. One hundred ng of pertussis 
toxin  (List Biological  Laboratories,  Campbell,  CA) was injected 
intravenously at  the  time  of immunization and again  2  d  later. 
Mice were assessed clinically  according to the following criteria: 
0, no disease; 1, tail atony; 2, hind-limb weakness;  3, hind-limb 
paralysis; 4, hind-limb paralysis and fore-limb paralysis or weak- 
ness; 5, moribund. 
Histological Analysis.  The paralyzed mice were sacrificed 30 d 
after primary challenge. The spinal cords and brains were removed 
and  fixed  in  10%  phosphate-buffered  formalin.  The  paraffin- 
embedded sections were stained with hematoxylin/eosin and ex- 
amined under light microscopy. 
Results 
Generation  of HLA-DRA-IEaee /HLA-DRB I* O4O I-IEaj8 
Tg mice.  We  produced  Tg  mice  with  chimeric  human- 
mouse MHC  class II genes that encode proteins composed 
of the antigen binding domains from HLA-DRA and HLA- 
DRBI*0401,  and  the  remaining  domains  from the  IEa-cx 
and -13 chains. We used IE genes, because HLA-DR. mole- 
cules bear more homology to IE than to IA at the  amino 
acid  sequence  level.  The  chimeric  gene  constructs  were 
manipulated  by  replacing  exon  2  of IEa-ot  or  IEd-]3  ge- 
nomic  DNA  with  gene  fragments  containing  exon  2  of 
HLA-DRA or HLA-DRB 1"0401 respectively, as described 
in Materials  and Methods. Tg mice produced by comicro- 
injection with the two gene constructs were backcrossed to 
MHC  class  II deficient  (IAI3-,IEex-) mice  (19).  As shown 
in  Fig.  1 A,  B220 +  cells  brighdy  expressed  the  chimeric 
MHC class II molecules, while CDllb + cells expressed them 
dimly. This expression pattern was the same as that of rou- 
tine MHC  class  II genes  (data not shown),  indicating that 
the  transgenes  were  expressed  in  a  regular,  tissue-specific 
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manner.  Since  it  has  been reported  that  endogenous  IE[3 
molecules can associate with the HLA-DRA chain and the 
resulting mixed heterodimers  are expressed  on the  cells in 
HLA-DRA Tg mice (20), we investigated  cell surface ex- 
pression of the HLA-DRA-IEex/IE[3 heterodimer.  The IE[3 
chain was not detected by FACS  |  analysis in 2 out of 5 Tg 
mouse lines.  Representative  Tg mouse lines are shown in 
Fig.  1 B.  Transgenic mice not expressing endogenous IE[3 
were used in the following experiments. 
T Cell Development in Tg Mice.  It has  been  shown  that 
mature,  MHC  class II-restricted CD4 + T  cells do not de- 
velop  in MHC  class  II-deficient mice  (19,  21).  This  evi- 
dence suggests that the  expression  of MHC  class  II mole- 
cules closely influences  the  development  of CD4 + T  cells 
in the thymus. Thus, we examined whether mouse T  cells 
could develop  properly in  a  human-mouse  MHC  class  II 
environment. As shown in Fig. 2, CD4 § T  cells developed 
normally in the  thymus and  spleen  of both  Tg  (IA-,IE-) 
mice and their non-Tg (IAb+,IE  -) littermates.  We next ex- 
amined  the  development  of  T  cell  repertoire  in  Tg 
(IA-,IE-)  mice  and  found  that  T  cells  expressing  V135-, 
V[311-, or VI312-TCR gene segments were specifically de- 
leted.  In contrast,  V]36 +  and V1310 +  T  cells  were  signifi- 
cantly increased in the spleen of Tg mice (Fig. 3). 
Antigen-binding  Specificity of HLA-DRB I* O4O I-IE Mole- 
cules.  Since  antigens  bind  to  the  first  domain  of MHC 
class II molecules, we expected similar antigen-binding speci- 
ficity between HLA-DRBI*0401-IE and HLA-DRBI*0401 
molecules.  The most crucial residues  in the peptide-bind- 
ing motifofHLA-DRBl*0401  are an aromatic or aliphatic 
anchor residue at position  1, and a residue with a hydroxyl 
group at position 6  (22).  Peptide ml-7  (YRAMATL) pos- 
sesses  the  full  binding  motif for  HLA-DRBI*0401,  and 
thus,  binds to HLA-DRBI*0401 with a high affinity (Ta- 
ble  1)  (23). We used substitutions at position 6 of ml-7 to 
compare the binding specificity of the  chimeric molecules 
with  that  of HLA-DRBI*0401.  As  shown  in  Table  1, 
amino acid substitutions at position 6 resulted in nearly iden- 
tical changes in binding affinity for both HLA-DRBI*0401 
and HLA-DRBI*0401-IE molecules. Although R6-ml-7 is 
an apparent exception, we should point out that the SPA pep- 
tide binding assay is less  sensitive  at peptide  concentration 
higher than  10 IxM, and the IC50 values, 3.3 and >10 I.tM, 
both indicate that the peptides are very poor binders or non- 
binders  for the  respective  molecules.  Therefore,  these  re- 
sults have indicated that the HLA-DRBI*0401-IE molecule 
mimics  the  HLA-DRBI*0401  molecule  in  terms  of pep- 
tide binding specificity. 
T Cell Response to Antigenic Peptides in Tg Mice.  To study the 
HLA-DRBl*0401-restricted  T  cell  response  in  Tg mice, 
Tg and  non-Tg mice were  immunized  with  HA307-319 
or HA-R6.  As shown  in  Table  1,  HA307-319  is  a  good 
binder  to  both  DRBI*0401  and  DRBI*0401-IE,  while 
HA-R6,  a peptide with Arg substituted  at position 314 of 
HA307-319  is  nearly  a  non-binder.  Immunization  of Tg 
mice with  HA307-319  elicited  T  cell proliferation,  while 
HA-R6  did not  (Fig.  4).  The  absence  of proliferative  re- 
sponse to HA-R6 is most likely due to a low binding affin- O 
v'4 
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Figure 1.  HLA-DRA-IEot/HLA- 
DRBI*0401-IEI3  heterodimer  is 
expressed in  B220- or  CDllb- 
positive population, while endoge- 
nous IEbl3 is not expressed in a no. 
45-1 Tg line. (A) Spleen cells from 
Tg mice were stained with anti- 
HLA-DR  mAb-FITC  and  anti- 
B220  mAb-PE  or  anti-CDllb 
mAb-PE. (13) Spleen cells fi:om  non- 
Tg, no. 45-1 Tg, and no. 39-2 Tg 
mouse lines were stained with anti- 
HLA-DR.  mAb or anti-IEI3  mAb. 
ity to HLA-DR_BI*0401-IE molecules since an Arg residue 
at  relative  position  6  of the binding motif is not tolerated 
(see  in  Table  1).  The  T  cell proliferation  to  HA307-319 
was inhibited by the anti-HLA-DP,, mAb, LB3.1. Immuni- 
zation ofnon-Tg mice with HA307-319 failed to elicit any 
T  cell proliferation  (Fig.  4).  These results  indicate that the T 
cell proliferation  was  HLA-D1L-restricted,  i.e.,  the  HLA- 
DRA-IEodHLA-DRBI*0401-IE[3  molecules  present  anti- 
gens effectively to T  cells in the Tg mice. 
Development of EAE in Tg Mice Immunized with PLP175- 
192 or MBP87-106.  The major imanunodominant epitopes 
of MBP  are  residues  87-106  and  143-168  for individuals 
with HLA-DR4 alleles.  Based on the peptide-binding mo- 
tif of HLA-DRBI*0401  (22)  and  peptide-binding  results 
using overlapping 20--amino acid peptides of PLP (12)  ~, we 
assumed  that  PLP175-192  could be  an  immunodominant 
epitope for HLA-DR4 individuals. As we expected, PLP175- 
192 binds HLA-DRBI*0401 as strongly as MBP87-106 (Ta- 
ble  1).  The  amino  acid  sequences  of PLP175-192  and 
MBP87-106 are identical between human and mouse, and 
thus,  they  represent  autoantigens  for  both  species.  We 
therefore  examined  the T  cell proliferative  responses with 
these peptides. As shown in Fig. 5 A, lymph node ceils from 
SJL/J  mice  immunized  with  MBP87-106  proliferated  in 
response  to the  antigen,  while little  or no proliferative  re- 
sponse was detected in Tg mice immunized with MBP87- 
106.  In  contrast,  immunization  with  PLP175-192  pro- 
voked a strong T  cell response  to this peptide in Tg mice 
(Fig. 5/3). T  cell response to PLP175-192 was inhibited by 
both  anti-DRot  mAb,  LB3.1,  and  anti-HLA-DP,[3  mAb, 
1-1C4 (24, 25), but not by anti-IEl3 mAb, 17.3.3 (Fig. 5/3). 
This  result  indicated  that  T  cell proliferation  to  PLP175- 
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Figure  2.  T  cell  development 
in  Tg  (IA-,  IE-)  mice.  Single 
cell suspensions  were  made  from 
thymus  and  spleen  and  stained 
with  anti-CD8  mAb-FITC  and 
anti-CD4  mAb-PE  as  described 
in Materials and Methods. 
192 was restricted by the transgenic class II molecule￿9 We 
then tested the development of EAE by immunizing with 
PLP175-192 or MBP87-106. As shown in Table 2 and Fig. 6, 
Tg  mice  immunized with  PLP175-192  showed  signs  of 
EAE 14-17 d after primary immunization. Most of the mice 
immunized with PLP175-192 showed a progression of symp- 
toms beginning with tail atony, followed by hind-limb pa- 
ralysis,  weakening of the  forelimbs  and  eventually death 
(Fig. 6). In contrast, Tg mice immunized with MBP87-106 
developed only a mild EAE. To examine that EAE was in- 
duced by DR4-restricted T cells, we used non-Tg/IA-,IE- 
mice as a negative control. The mice did not develop the dis- 
ease, thus the EAE development was mediated by DR4-IE 
chimeric molecules. Histological studies of the spinal  cord 
and brain from the paralyzed Tg mice revealed numerous 
inflammatory foci in white matter, and demyelination and 
axonal degeneration of nerves were observed in the spinal 
cord (Fig. 7). The results have indicated that HLA-DRA- 
IEc~/HLA-DRBI*0401-IE~3  Tg  mice  are  susceptible  to 
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EAE, and that PLP175-192 is a more potent encephalito- 
genic epitope than MBP87-106 in these mice. 
Discussion 
To  study  the  development  of HLA-DR4-1inked  au- 
toimmune diseases, we generated transgenic mice possess- 
ing HLA-DR4-IE chimeric MHC class II genes, because it 
was unclear whether the murine CD4 molecule could be 
activated by HLA-DR4 molecules as effectively as it could 
be by mouse MHC class II molecules. Although it has been 
reported that murine CD4 interacts well with HLA-DR1 
molecules (26),this cannot be extrapolated directly to HLA- 
DR4  molecules,  since  human  CD4  does  not  interact 
equally well with all HLA-DR allotypes (27). Additionally, 
the cytoplasmic tail of MHC class II molecules plays an im- 
portant  role  in  T  cell activation and in  the  recycling of 
MHC class II molecules (28). Signal transduction from the 
cytoplasmic tail regulates the development of Thl/Th2 T > 
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Figure 3.  TCR  VI3  expression 
on CD4 + T cells in spleen. Sple- 
nocytes  were  stained with  PE- 
conjugated anti-CD4 mAb and bi- 
otinylated  anti-TCR  VI3  mAbs, 
and FITC-streptavidin was used in 
the second step staining. Percent- 
age of the cells which express both 
CD4 and TCR V~ in a C1)4  + T 
cell population was calculated. Er- 
ror  bars represent  SD  of  three 
mice.  I,  C57BL/6;  [],  Tg 
(IA-,IE-). 
helper cells through the activation of B7 molecules (29), and 
this  signal might  be  critical for  the  development  of auto- 
immune diseases. Thus,  human/mouse  chimeric class II gene 
constructs appeared to be a better choice than fi.fll HLA-DR 
genes  for production  of HLA-DR  Tg mice.  However,  we 
could not completely rule out the possibility that the joining 
of human first domains to murine second domains would pro- 
duce an altered conformation of the human antigen binding 
site.  Thus,  we  compared  the  antigen-binding specificity of 
HLA-DRBI*0401  and HLA-DRBI*0401-IE molecules, re- 
spectively. The specificity and affinity of antigen-binding by 
these molecules were very similar (Table 1).  We also exam- 
ined the peptide-binding specificity of  another chimeric mole- 
cule we  constructed,  HLA-DRBI*0404-IE  molecules.  The 
peptide-binding  specificity to  HLA-DRBI*0404-IE  mole- 
cules showed the same specificity to HLA-DRB1*0404 mole- 
cules (unpublished observation). These results indicated that 
HLA-DR4-IE  molecules could  substitute  the  HLA-DR4 
molecules with respect to first domain-dependent functions 
in Tg mice. 
As shown in Fig. 4  and previous reports (1, 2),  HA307- 
319 specific DR4-restricted T  cells were elicited to proliferate 
in Tg mice after immunization with the peptide. We next 
examined whether HA307-319-specific human T  cell clones 
could be activated by the peptide presented by HLA-DR4- 
IE chimeric molecules. Although the clones were activated 
by  HA307-319  presented  by  native  DR4  molecules  ex- 
pressed  on  murine  fibroblast cells, they were  barely acti- 
vated by the  same peptide presented  on  splenocytes from 
Tg mice (data not shown). This suggested that the associa- 
tion  of human  CD4  molecules with  the  chimeric  class II 
was insufficient to activate these T  cells. 
To eliminate any influence of endogenous MHC  class II 
on  the  development  of autoimmune  disease,  the  HLA- 
DR4-IE Tg mice were backcrossed to MHC  class II-defi- 
cient (IA~-,IEot-) mice. Endogenous  IE[3  associated with 
HLA-DRA-IE0t  was  not  detected  by  FACS  |  analysis in 
certain Tg mouse lines  (see in Fig.  1  B).  Mice which  ex- 
press IE[3  have low copy number of transgene  (1-10  cop- 
ies), while IE[3-non-expressing mice have high copy num- 
ber  (70-120  copies).  Thus,  the  difference  in  expression 
might be due to either a dilution of mixed DRA-IEo#IE[3 
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Figure 4.  T cell proliferation in Tg and non-Tg mice immunized with 
antigenic peptides. Lymph node ceils  were isolated from mice immunized 
with antigen in CFA. Cells were cultured with antigen in the presence or 
absence of 20  p.g/ml of anti-DR mAb, LB3.1. Proliferative responses 
were measured as described in Material and Methods. I, HA307-319; 0, 
HA-R6; A, HA307-319/anti-DR  n~b; 0, HA307-319/Non-Tg. 
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Figure 5.  T cell response to MBP87-106  and PLP175-192  in Tg mice. 
(A) T cell proliferative response to MBP87-106.  Tg mice and SjL/j mice 
were immunized with MBP87-106  and proliferation  of lymph node cells 
in response to MBP87-106  was measured. (13) T cell prohferative response 
of Tg mice to PLP175-192  and its inhibition by anti-DR mAbs. Lymph 
node  cells from Tg mice immunized with PLP175-192  were cultured 
with various concentrations  of PLP175-192  in the presence or absence of 
20 I~g/ml ofanti-DRa (LB3.1), anti-DR.13 (1-1C4)  or anti-IE[3 (17.3.3) 
mAbs. (A) [3, SJL/J/mice; O, Tg mice; (B) O, PLP174-191;  Q, PLP174- 
19/anti-IE[3  mAb;  ￿9  PLP174-191/anti-DP, et  mAb;  ￿  PLP174-191/ 
anti-DR[3  mAb. 
Table 2.  Development  of EAE in DRBI*O4OI-IE  Tg Mice 
Severity 
Onset Day 
Antigen  Mice  Incidence  (mean)  0  1  2  3  4  5 
PLP 175-192  Tg  5/5  15  0  0  0  0  1  4 
+  CFA  Non-Tg  0/5  -  5  0  0  0  0  0 
MBP87-106  Tg  3/5  16  2  2  0  1  0  0 
+  CFA  Non-Tg  0/5  -  5  0  0  0  0  0 
CFA  Tg  0/5  -  5  0  0  0  0  0 
Clinical scoring is described  in Materials and Methods. 
differential gene expression.  We  also examined the associa- 
tion  of endogenous  IAcx chain  with  HLA-DRBI*0401-IE[3 
protein and their cell-surface expression using the mice car- 
wing a single HLA-DRBI*0401-IE[3 transgene.  The mixed 
heterodimer  was  not  detected by  1-1C4  mAb  specific for 
the HLA-DIL[3 chain  (data not shown).  These results have 
demonstrated  that  the Tg mice do not express any murine 
class II chains on the cell surface. 
In the  Tg mice,  the  thymus  and  spleen were  of normal 
architecture.  However, the V[35-,V[311-,V[312-,  and V[317- 
expressing  T  cell subsets  were  strongly  diminished  or  ab- 
sent  from Tg mice.  A  similar observation  was  reported  in 
double Tg mice with DRBI*0401  and human  CD4  genes 
(2). The lack ofVl317-bearing T  cells is due to a deficiency 
of the V[317  gene in C57BL/6  mice. C57BL/6  mice carry 
mouse  mammary  tumor  viruses  (MMTV)  -8,-9,  and  -17 
5- 
4- 
3- 
2- 
0  O---O  O  0 
I  I  I  !  I  I  I 
10  15  20  25  30  35  40  45 
molecules  caused  by  the  high  expression  of DRBI*0401- 
IE~  molecules,  or decreased  transcription  of the  IEI3 gene 
due  to  limiting  amounts  of transcription  factors.  Experi- 
ments are currently in progress to clarify the mechanism of 
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Days after primary challenge 
Figure 6.  EAE development in Tg mice in response to PLP175-192. 
Clinical score is described in Materials and Methods.  Error bars represent 
SD of five mice in Table 2. IS], Tg mice; O, Non-Tg mice. Figure 7.  Histopathological  analysis of  spinal cord and brain from a paralyzed  Tg mouse with PLP175-192. The magnification of  pictures of(A) Spinal 
cord and (B) Brain is ￿ 
(30),  which bind  to IE and delete  T  cells  expressing V[35, 
VI311,  and  V[312  TCR  segments  (31).  Thus,  MMTV- 
encoded superantigens  could bind to HLA-DR4-IE mole- 
cules and the MHC  class  II complexes with the superanti- 
gens deleted these T  cell subsets. 
As  shown  in  Table  1  and  Fig.  5  A,  although  SJL mice 
developed a proliferative T  cell response to MBP87-106,  a 
response  was barely detectable  in  Tg mice in  spite  of the 
binding of  MBP87-106 to DRBI*0401-IE molecules. A pos- 
sible explanation for this discrepancy is that the thymic pos- 
itive  selection  for MBP87-106-specific  T  cells  is  different 
between  SJL and Tg mice because of their different MHC 
class I1 haplotypes. However, since MBP87-106 reactive T 
cells  have been isolated from HLA-DRBI*0401 humans, it 
is  more likely that  the  relevant  specificity is  missing from 
the  TCR  repertoire  of Tg mice.  This  may be  due  to  the 
limited homology of TCR genes between human and mouse 
(32),  or the  deletion  of certain  T  cell  subsets  by endoge- 
nous  MMTV  integrants.  Similar  results  were  observed  in 
SJL-TCR V[38.2 Tg mice, which had a limited T  cell rep- 
ertoire because ofallelic exclusion by the transgene  (33). In 
these mice, immunization with a PLP peptide elicited a strong 
T  cell proliferation, while immunization with MBP87-106 
barely stimulated T  cells.  The result suggests that the TCI~ 
diversity  of MBP87-106-reactive  T  cells  is  more  limited 
than that of PLP175-192-specific T  cells.  The same expla- 
nation  may  apply  to  the  minimally-detectable  T  cell  re- 
sponse to MBP87-106  in  our DR4-IE Tg mice.  The fact 
that these Tg mice developed mild EAE when immunized 
with  MBP87-106  suggests  that  a  small  population  of en- 
cephalitogenic  MBP87-106  specific  T  cells  does  exist. 
However this T  cell population may be too small to be de- 
tected in the primary T  cell proliferation assay. 
Herein,  we have demonstrated  that HLA-DRBI*0401- 
IE  restricted  T  cells  specific  for PLP175-192  or MBP87- 
106 peptides cause encephalomyelitis in HLA-DR Tg mice. 
Thus, PLP175-192 and MBP87-106 could be encephalito- 
genic epitopes in individuals with HLA-DRB 1"0401 allele. 
The  results  also  demonstrate  that  a  human  MHC  class  II 
binding site alone can confer susceptibility to autoimmune 
disease.  The Tg mice reported here will be useful to study 
autoantigens involved in the development of other autoim- 
mune diseases  associated with the HLA-DRBI*0401 allele. 
We would like to thank Dr. Haruo Saito for providing us IEa[3 cosmid DNA; Dr. David A. Hailer for the 
information  of immunodominant epitopes  of PLP in HLA-DR2 MS patients; Michelle  Fanale, Raymond 
Makofske, Donald Cox, Diana Gaizband, and Himanshu Shah for excellent technical assistance; Doug Larri- 
gan, Joseph Levine and John Duker for DNA sequencing; P,  ongshen Hsiao and Ludmilla Foppiani for oligo- 
nucleotides  synthesis; Drs.  Werner Haas and  Kathy Myers  for critically reading  the manuscript;  and  Dr. 
Michael Steinmetz for encouragement. 
Address correspondence  to Kouichi Ito, Department of Inflammation and Autoimmune Diseases, Hoffman- 
La Roche, Inc., Bldg. 123, Rm 4331, 340 Kingsland St., Nufley,  NJ 07110-1199. 
Received  for publication 27 December 1995 and in revised  form  14 March 1996. 
2642  Experimental  Allergic Encephalomyelitis  in HLA-DP,4-IE Tg Mice References 
1.  Woods, A., H.Y.  Chen,  M.E.  Trumbauer,  A.  Sirotina, R. 
Cummings, and D.M. Zaller. 1994.  Human major histocom- 
patibility complex class II-restricted T  cell responses in trans- 
genic mice.J. Exp. Med.  180:173-181. 
2.  Fugger, L.,  S.A. Michie,  I.  Rulifson,  C.B.  Lock,  and  G.S. 
McDevitt. 1994.  Expression of HLA-DR4 and human CD4 
transgenes in mice determines the variable region [3-chain 
T-cell repertoire and  mediates an  HLA-DR-restricted im- 
mune response. Proc. Natl. Acad. Sci. USA. 91:6151-6155. 
3.  Nabozny, G.H., J.M. Baisch, S. Cheng, D. Cosgrove, M.M. 
Griffiths,  H.S.  Luthra,  and  C.S.  David.  1996.  HLA-DQ8 
transgenic mice are highly susceptible to collagen-induced ar- 
thritis: a novel model for human  polyarthritis. J.  Exp.  Med. 
183:27-37. 
4.  Pettinelli, C.B., R.B. Fritz, H.J. Chou C, and D.E.J. McFar- 
lin. 1982.  Encephalitogenic activity of guinea pig myelin ba- 
sic protein in the SJL mouse. Immunology. 129:1209-121 l. 
5.  Fritz, R.B., H.J. Chou C, and D.E. McFarlin. 1983.  Relaps- 
ing routine experimental allergic encephalomyelitis induced 
by myelin basic protein.J. Immunol.  130:1024-1026. 
6.  Enddoh,  M.,  T.  Tabira,  T.Kunishita,  K.  Sakai,  T.  Yama- 
mura, and T. Taketomi. 1986. DM-20, a proteolipid apopro- 
tein, is an encephalitogen of acute and relapsing autoimmune 
encephalomyelitis in mice. J, Immunol.  137:3832-3835. 
7.  Zamvil, S.,  P.  Nelson, J.  Trotter,  D.  Mitchell, R.  Knobler, 
R.  Fritz, and L.  Steinman.  1985.  T-cell clones specific for 
myelin basic protein induce  chronic relapsing paralysis and 
demyelination. Nature (Lond.). 317:355-358. 
8.  Ota,  K.,  M.  Matsui,  E.L.  Milford,  G.A.  Mackin,  H.L. 
Weiner, and D.A. Hailer. 1990.  T-cell recognition of an im- 
munodominant myelin basic protein epitope in multiple scle- 
rosis. Nature (Land.). 346:183-187. 
9.  Martin, R., D. Jaraquemada, M. Flerlage,  J. Richert, J. Whit- 
aker, E.O.  Long, D.E. Mcfarlin, and H.F. Mcfarland. 1990. 
Fine specificity and HLA restriction of myelin basic protein- 
specific cytotoxic T  cell lines from multiple sclerosis patients 
and healthy individuals.  J. Immunol.  145:540-548. 
10. Pette, M., K. Fujita, D. Wilkinson, D.M. Altmann, J. Trows- 
dale G.  Giegerich, A. Hinkkanen, J.T.  Epplen,  L.  Kappos, 
and  H.  Wekerle.  1990.  Myelin  autoreactivity in  multiple 
sclerosis: Recognition of myelin basic protein in the context 
of HLA-DR2 products by T lymphocytes of multiple-sclero- 
sis patients and healthy donors. Proc. Natl. Acad. Sci. USA. 87: 
7968-7972. 
11. Martin, R., U. Utz, J.E.  Coligan, J.R. Richert, M.  Flerlage, 
E. Robinson, R.  Stone, W.E. Biddison, D.E. McFarlin, and 
H.F. McFarland. 1992. Diversity in fine specificity and T  cell 
receptor usage of the human CD4 + cytotoxic T  cell response 
specific for the immunodominant myelin basic protein pep- 
tide 87-106._/.  Immunol.  148:1359-1366. 
12. Markovic-Plese, S., H. Fukaura, J. Zhang, A. A1-Sabbagh, S. 
Southwood, A. Sette, V.K. Kuchroo, and D.A. Hailer. 1995. 
T  cell recognition of immunodominant and cryptic proteo- 
lipid protein epitopes in humans.J. Immunol.  155:982-992. 
13. Zhang, J., S. Markovic-Plese, B. Lacet, J. Raus, H.L. Weiner, 
and D.A.  Hailer.  1994.  Increased frequency of Interleukin 
2-responsive T cell specific for myelin basic protein and pro- 
teolipid protein in peripheral blood and cerebrospinal fluid of 
patients with multiple sclerosis._/. Exp. Med.  179:973-984. 
14. Kawai, J., A. Ando, T.  Sato, T. Nakatsuji, K. Tsuji, and H. 
Inoko. 1989. Analysis of gene structure and antigen determi- 
nants of DR2 antigens using DR gene transfer into mouse L 
2643  Ito et al. 
cells../. Immunol.  142:312-317. 
15. Steinmetz,  M.,  K.  Minard,  S.  Horvath, J.  McNicholas, J. 
Frehnger, C. Wake, E. Longe, B. Mach, and L. Hood. 1982. 
A  molecular map of the immune response region from the 
major  histocompatibility  complex  of  the  mouse.  Nature 
(Land.). 300:35-42. 
16. Saito, H., R.A. Maki, L.K. Clayton, and S. Tonegawa. 1983. 
Complete primary structures of the E[3 chain and gene of the 
mouse  major histocompatibility complex.  Proc. Natl.  Acad. 
Sci. USA. 80:5520-5524. 
17. Barany,  G., and R.B.  Merrifield. 1980.  The  Peptides. Aca- 
demic Press, New York. 2:1-287. 
18. Glimcher, L.H.,  D.J.  McKean,  E.  Choi,  and  G.  Seidman. 
1985. Complex regulation of class I1 gene expression: analysis 
with class II mutant cell lines.J. Immunol.  135:3542-3550. 
19. Grusby,  M.J.,  R.S. Johnson,  V.E.  Papaioannou,  and  L.H. 
Glimcher. 1991.  Depletion of CD4 + T  cells in major histo- 
compatibility complex class II-deficient mice. Science (Wash. 
DC). 253:1417-1420. 
20.  Lawrance, S.K., L. Karisson, J. Price, V. Quaranta, Y. Ron, J. 
Sprent,  and  P.A.  Peterson.  1989.  Transgenic  HLA-DRo~ 
faithfully reconstitutes IE-controlled immune  functions and 
induces cross-tolerance to Ece in Eo~  ~ mutant mice. Cell. 58: 
583-594. 
21. Gosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur, 
C. Benoist, and D. Mathis. 1991. Mice lacking MHC class II 
molecules. Cell. 66:1051-1066. 
22. Hammer, J., P. Valsasnini,  K. Tolba, D. Bolin, J. Higelin, B. 
Takacs, and F. Sinigaglia. 1993.  Promiscuous and allele-spe- 
cific anchors in HLA-DR-binding peptides. Cell. 74:197-203. 
23. Hammer, J., C. Belunis, D. Bolin, J. Papadopoulos, R. Wal- 
sky, J.  Higelin, W.  Danho,  F.  Sinigaglia, and  Z.A.  Nagy. 
1994.  High affinity binding of short peptides to MHC class II 
molecules  by  anchor  combination.  Proc. Natl.  Acad.  Sci. 
USA. 9l :4456-4460. 
24. Cammarota,  G.,  A.  Scheirle, B.  Takacs,  D.M.  Doran,  R. 
Knorr, W. Bannwarth, J.  Guardiola, and F. Sinigaglia. 1992. 
Identification of a CD4 binding domain of HLA-DR mole- 
cule. Nature (Land.). 356:799-801. 
25. Vidovi~, D., F. Falcioni, B. Siklodi, C.J. Belunis, D.R. Bolin, 
K. Ito, and Z.A. Nagy. 1996. Downregulation of Class II ma- 
jor histocompatibility  complex molecules on antigen-presenting 
cells by antibody fragments. Eur.J. Immunol.  25:3349-3355. 
26. Altmann, D.M.,  D.C.  Douek, A.J.  Frater, C.M. Hethering- 
ton, H. Inoko, and J.I. Elliott. 1995.  The T  cell response of 
HLA-DR transgenic mice to human myelin basic protein and 
other antigens in the presence and absence of human CD4. J. 
Exp. Med.  181:867-875. 
27.  Fleury, S., J.  Thibodeau,  G.  Croteau,  N.  Labrecque,  H.E. 
Aronson,  C.  Cantin,  E.O.  Long,  and  R.P.  Sekaly.  1995. 
HLA-DR polymorphism affect the interaction with CD4. J. 
Exp. Med.  182:733-741. 
28. Pinet, V., M. Vergelli, R. Martin, O. Bakke, and E.O. Long. 
1995.  Antigen presentation mediated by recycling of surface 
HLA-DR molecule. Nature (Land.). 375:603-606. 
29. Kuchroo,  V.K.,  M.P.  Das, J.A. Brown,  A.M.  Ranger,  S.S. 
Zamvil,  R.A.  Sobel,  H.L.  Weiner,  N.  Nabavi,  and  L.H. 
Glimcher. 1995.  B7-1 and B7-2 costimulatory molecules ac- 
tivate  differentially the  Thl/Th2  developmental pathways: 
Application to autoimmune disease therapy. Cell. 80:707-718. 
30. Lee,  B.K.,  and E.M.  Eicher.  1995.  Segregation patterns of 
endogenous mouse mammary tumor viruses in five recombi- nant inbred strain sets.J.  Virol. 64:4568-4572. 
31.  Scherer, M. T., L. Ignatowicz, A. Pullen, J.  Kappler, and P. 
Marraek. 1995. The use of mammary tumor virus (Mtv)-neg- 
ative and single-Mtv mice to evaluate the effects of endoge- 
nous viral superantigens on the T cell repertoire.J. Exp. Med. 
182:1493-1504. 
32.  Lai, E., P. Concannon, and L. Hood. 1988.  Conserved orga- 
nization of the  human  and  murine  T-cell receptor [3-gene 
families. Nature (Lond.). 331:543-546. 
33.  Kuchroo, V.K., M. Collins, A. A1-Sabbagh, R.A. Sobel, M.J. 
Whitters,  S.S.  Zamvil,  M.E.  Doff,  D.A.  Hailer,  J.G. 
Seidman, H.L. Weiner, and I.J. Rimm. 1994. T  cell receptor 
(TCR) usage detenmnes disease susceptibility in experimen- 
tal autoimmune encephalomyelitis: studies with TCR VI3 8.2 
transgenic mice.J. Exp. Med.  179:1659-1664. 
2644  Experimental Allergic Encephalomyelitis in HLA-DR4-IE Tg Mice 